It was a dull day in the stock markets as weak
earnings coupled with the U.S. Fed Reserve keeping to its current course kept
sentiments low.
U.S. stock ended lower for the second straight day on
Wednesday.
The Dow Jones Industrial Average (INDEXDJX:.DJI) closed
down 25.19 points, or 0.19 percent, at 13,077.34 The S&P 500(INDEXSP:.INX) fell
4.36 points, or 0.31 percent, at 1,408.75. The NASDAQ Composite
(INDEXNASDAQ:.IXIC) slipped 8.77 points,
or 0.29 percent, at 2,981.70.
The currency market did not have mc to cheer about
either.
Unexpectedly weak German data saw the euro fall
against the dollar and yen.
But the euro's declines were limited after Greece's
finance minister said Athens had been given additional time by international
lenders to impose its austerity cuts.
The euro hit a session low of $1.2918, the lowest in a
week, before paring losses to last trade at $1.2972, down 0.1 percent for the
day.
On the earnings side it was all rather bleak, with
many companies issuing weaker outlooks for the current quarter.
Of the 161 companies in the S&P 500 that have
reported earnings so far, 60 percent have beaten analysts' estimates, a rate
that is down from about 67 percent the past four quarters.
Earnings are expected to decline 2.2 percent compared
with the year-ago quarter.
On the macro side the U.S. Fed said that it would keep
interest rates near zero until mid-2015 and pledged to continue to support
growth while the economy recovers.
It also proposed no changes to its $40 billion bond
buying program of mortgage-backed debt to keep interest rates low and spur
recovery.
A123 Systems, Inc.(NASDAQ:AONE) extended its downtrend
in Wednesday’s session as well and slumped 33.33% to $0.108. The stock fell
about 80% in one day last after filling for bankruptcy. However, in the next
few sessions, the stock recovered about 280% on the news that the company
automotive division was bought
by Johnson Controls Inc.
Pharma sector done well with Pfizer Inc.(NYSE:PFE)
rose 0.50% to $25.30. Gilead Sciences, Inc.(NASDAQ:GILD) soared 5.30% after
Revenue rose more than 14 percent to $2.43 billion thanks mainly to sales of
Atripla, Truvada and Viread. Net income fell to $675 million which works out to
85 cents a share compared to $741 million or 95 cents a share earned in the
same period last year.
Monster Beverage Corp(NASDAQ:MNST) recovered 17% after
the company defended the safety of its products. Investors fled the company
earlier in the week on news that the Food and Drug Administration was
investigating reports that five people died after drinking the company's
caffeine-packed drinks.
No comments:
Post a Comment